RE:RE:AGM news Attached is today’s news release about strengthening our Intellectual Property (IP) estate and building value for the company. As usual, here is some background:
1. The original AI (KBR) was licensed from the University of Washington for right ventricle analysis.
2. Over several years, the company improved the KBR and built better catalogues of diseased hearts to achieve equivalency to MRI.
3. The license was extended to include all 4 chambers of the heart and catalogues were built and validate for the atria and the left ventricle. These catalogues remain proprietary to the Company and are a major piece of its intellectual property estate, which include copy-write for software code, trademarks, patents and knowhow. It has taken years and thousand of person days to create the catalogues and code.
4. The company invented and filed a patent application for a new tracking system for 2D ultrasound.
5. The company invented and filed a patent application for a new way to measure 4D (motion) in hearts which apply to 2D and 3D ultrasound exams.
6. In 2020, the company completely rewrote the source code for the KBR and the application and added many features to improve security and user experience.
6. Now the Company has invented and filed a patent application for template-based analysis, which speeds up the analysis as well as making it more reliable by reducing operator variations on anatomical landmark placement.
7. Our primary motivation is to improve heart analysis and our creative team has come up with some very novel way to do this and we are protecting our right to commercialize them exclusively.
8. Biomedical companies are valued for their IP estates as this allows exclusive access to the market for decades. Companies often get bought just for their IP estate, as larger companies can exploit these exclusive rights more effectively.
9. Shareholder value is built by sales, IP and partnerships. 2021 continues to be a good year.
Thanks for your ongoing interest and support.
Please note our virtual AGM is today at 11:00 am EDT. Below is the contact information. Please join us if you can.
Regards,
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT
519-803-6937